Breaking News

Pfizer Signs $425m Flu Vaccine Deal with BioNTech

Collaboration to develop mRNA-based vaccines for prevention of influenza

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BioNTech AG, a biotech focused on precise immunotherapies for the treatment of cancer and infectious disease, has entered into a multi-year R&D collaboration with Pfizer to develop mRNA-based vaccines for prevention of influenza (flu). BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTec...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters